CR10701A - Compuestos de biaril eter urea - Google Patents

Compuestos de biaril eter urea

Info

Publication number: CR10701A
Authority: CR; Costa Rica
Prior art keywords: biaril; eter; urea compounds; urea; compounds
Prior art date: 2006-10-18

Application number

CR10701A

Other languages

English (en)

Inventor

Lorraine Kathleen Fay

Douglas Scott Johnson

Scott Edward Lazerwith

Mark Anthony Morris

Lijuan Jane Wang

Marvin Jay Meyers

Suzanne Ross Kesten

Cory Michael Stiff

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-18

Filing date

2009-03-31

Publication date

2009-04-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39314409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10701(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-31 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2009-04-30 Publication of CR10701A publication Critical patent/CR10701A/es

Links

XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Hematology (AREA)
Dermatology (AREA)
Otolaryngology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CR10701A 2006-10-18 2009-03-31 Compuestos de biaril eter urea CR10701A (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82996606P	2006-10-18	2006-10-18
US96521007P	2007-08-17	2007-08-17

Publications (1)

Publication Number	Publication Date
CR10701A true CR10701A (es)	2009-04-30

Family

ID=39314409

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CR10701A CR10701A (es)	2006-10-18	2009-03-31	Compuestos de biaril eter urea
CR20140313A CR20140313A (es)	2006-10-18	2014-06-27	Compuestos de biaril éter urea

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CR20140313A CR20140313A (es)	2006-10-18	2014-06-27	Compuestos de biaril éter urea

Country Status (38)

Country	Link
US (1)	US8044052B2 (es)
EP (1)	EP2076508B1 (es)
JP (1)	JP4434313B2 (es)
KR (1)	KR101181194B1 (es)
CN (1)	CN101595102B (es)
AP (1)	AP2780A (es)
AR (1)	AR063331A1 (es)
AT (1)	ATE493984T1 (es)
AU (1)	AU2007311591B2 (es)
BR (1)	BRPI0717596B8 (es)
CA (1)	CA2663984C (es)
CL (1)	CL2007003000A1 (es)
CR (2)	CR10701A (es)
CY (1)	CY1111170T1 (es)
DE (1)	DE602007011793D1 (es)
DK (1)	DK2076508T3 (es)
EA (1)	EA015488B1 (es)
ES (1)	ES2357340T3 (es)
GE (1)	GEP20125425B (es)
HN (1)	HN2007000407A (es)
HR (1)	HRP20110158T1 (es)
IL (1)	IL197664A (es)
MA (1)	MA30801B1 (es)
ME (1)	ME01308B (es)
MX (1)	MX2009004233A (es)
MY (1)	MY145460A (es)
NO (1)	NO342266B1 (es)
NZ (1)	NZ575624A (es)
PE (1)	PE20081265A1 (es)
PL (1)	PL2076508T3 (es)
PT (1)	PT2076508E (es)
RS (2)	RS20090154A (es)
SI (1)	SI2076508T1 (es)
TN (1)	TN2009000138A1 (es)
TW (1)	TWI404715B (es)
UY (1)	UY30649A1 (es)
WO (1)	WO2008047229A2 (es)
ZA (1)	ZA200902548B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006074025A1 (en)	2004-12-30	2006-07-13	Janssen Pharmaceutica N.V.	Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
JO3598B1 (ar)	2006-10-10	2020-07-05	Infinity Discovery Inc	الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
GEP20125425B (en)	2006-10-18	2012-03-26	Pfizer Prod Inc	Biaryl ether urea compounds
AU2009233711B2 (en)	2008-04-09	2015-02-12	Infinity Pharmaceuticals, Inc	Inhibitors of fatty acid amide hydrolase
WO2009127948A1 (en) *	2008-04-17	2009-10-22	Pfizer Inc.	4- [3- (aryloxy) benzylidene] -3-methyl piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
WO2009127944A1 (en) *	2008-04-17	2009-10-22	Pfizer Inc.	Ether benzylidene piperidine aryl carboxamide compounds useful as faah inhibitors
US20110053949A1 (en) *	2008-04-17	2011-03-03	Pfizer Inc.	4-[3-(aryloxy)benzylidene]-3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
EP2276738A1 (en) *	2008-04-17	2011-01-26	Pfizer Inc.	Ether benzylidene piperidine 5-membered aryl carboxamide compounds useful as faah inhibitors
JP2011518144A (ja) *	2008-04-17	2011-06-23	ファイザー・インク	Ｆａａｈ阻害剤として有用な４−ベンジリデン−３−メチルピペリジンアリールカルボキサミド化合物
US8461159B2 (en)	2008-11-25	2013-06-11	Jannsen Pharmaceutica BV	Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8598356B2 (en)	2008-11-25	2013-12-03	Janssen Pharmaceutica Nv	Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
WO2010064597A1 (ja) *	2008-12-01	2010-06-10	武田薬品工業株式会社	ピペリジン誘導体
CA2747419C (en)	2009-01-12	2014-07-08	Icagen, Inc.	Sulfonamide derivatives
WO2010118155A1 (en)	2009-04-07	2010-10-14	Infinity Pharmaceuticals, Inc.	Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en)	2009-04-07	2010-10-14	Infinity Pharmaceuticals, Inc.	Inhibitors of fatty acid amide hydrolase
WO2010124113A1 (en)	2009-04-23	2010-10-28	Infinity Pharmaceuticals, Inc.	Anti-fatty acid amide hydrolase-2 antibodies and uses thereof
US8927551B2 (en)	2009-05-18	2015-01-06	Infinity Pharmaceuticals, Inc.	Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en)	2009-05-18	2015-10-06	Infinity Pharmaceuticals, Inc.	Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en)	2009-05-18	2014-07-01	Infinity Pharmaceuticals, Inc.	Isoxazolines as inhibitors of fatty acid amide hydrolase
WO2010141809A1 (en)	2009-06-05	2010-12-09	Janssen Pharmaceutica Nv	Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase
US20120083476A1 (en)	2009-06-05	2012-04-05	Janssen Pharmaceutica Nv	Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
ES2626246T3 (es)	2009-09-09	2017-07-24	Sumitomo Dainippon Pharma Co., Ltd.	Derivado de 8-oxodihidropurina
WO2011077313A1 (en)	2009-12-22	2011-06-30	Pfizer Inc.	Piperidinecarboxamides as mpges - 1 inhibitors
US20130150346A1 (en)	2010-01-08	2013-06-13	Quest Ventures Ltd.	Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
BR112012019120A2 (pt)	2010-02-03	2016-06-28	Infinity Pharmaceuticais Inc	forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah
WO2011104649A1 (en)	2010-02-25	2011-09-01	Pfizer Limited	Peptide analogues
WO2011123719A2 (en)	2010-03-31	2011-10-06	Ironwood Pharmaceuticals, Inc.	Use of faah inhibitors for treating abdominal, visceral and pelvic pain
UA108233C2 (uk)	2010-05-03	2015-04-10		Модулятори активності гідролази амідів жирних кислот
WO2012004743A1 (en)	2010-07-09	2012-01-12	Pfizer Limited	Benzenesulfonamides useful as sodium channel inhibitors
ES2526675T3 (es)	2010-07-09	2015-01-14	Pfizer Limited	N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
EP2593431B1 (en)	2010-07-12	2014-11-19	Pfizer Limited	N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
EP2593427B1 (en)	2010-07-12	2014-12-24	Pfizer Limited	Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2804351A1 (en)	2010-07-12	2012-01-19	Pfizer Limited	Chemical compounds
EP2593428B1 (en)	2010-07-12	2014-11-19	Pfizer Limited	N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013532184A (ja)	2010-07-12	2013-08-15	ファイザー・リミテッド	電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
WO2012095781A1 (en)	2011-01-13	2012-07-19	Pfizer Limited	Indazole derivatives as sodium channel inhibitors
EP2694509B1 (en)	2011-04-05	2016-05-18	Pfizer Limited	Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
WO2013008123A1 (en)	2011-07-13	2013-01-17	Pfizer Limited	Enkephalin analogues
WO2013042139A1 (en) *	2011-09-23	2013-03-28	Advinus Therapeutics Limited	Amide compounds, compositions and applications thereof
WO2013054185A1 (en)	2011-10-13	2013-04-18	Pfizer, Inc.	Pyrimidine and pyridine derivatives useful in therapy
BR112014009102A2 (pt)	2011-10-26	2017-04-18	Pfizer Ltd	compostos químicos
EP3243815B1 (en)	2011-10-28	2019-07-10	Inhibitaxin Limited	Pyridazine derivatives useful in therapy
ES2593533T3 (es)	2011-12-15	2016-12-09	Pfizer Limited	Derivados de sulfonamida
WO2013093688A1 (en)	2011-12-19	2013-06-27	Pfizer Limited	Sulfonamide derivatives and use thereof as vgsc inhibitors
CA2860553C (en)	2012-01-04	2016-08-23	Pfizer Limited	N-aminosulfonyl benzamides
WO2013114250A1 (en)	2012-02-03	2013-08-08	Pfizer Inc.	Benziimidazole and imidazopyridine derivatives as sodium channel modulators
CA2885259A1 (en)	2012-10-04	2014-04-10	Pfizer Limited	Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
CA2885247A1 (en)	2012-10-04	2014-04-10	Pfizer Limited	Tropomyosin-related kinase inhibitors
JP2015531394A (ja)	2012-10-04	2015-11-02	ファイザー・リミテッドＰｆｉｚｅｒＬｉｍｉｔｅｄ	ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
US9630896B2 (en)	2013-11-22	2017-04-25	Tansna Therapeutics, Inc.	2,5-dialkyl-4-H/halo/ether-phenol compounds
WO2017007755A1 (en)	2015-07-06	2017-01-12	Rodin Therapeutics, Inc.	Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
HUE057041T2 (hu)	2015-07-06	2022-04-28	Alkermes Inc	Hiszton deacetiláz hetero-halogén gátlói
MA47212A (fr)	2017-01-06	2019-11-13	Yumanity Therapeutics Inc	Méthodes de traitement de troubles neurologiques
HRP20220223T1 (hr)	2017-01-11	2022-04-29	Alkermes, Inc.	Biciklički inhibitori histon deacetilaze
MX2021009594A (es)	2017-06-30	2022-10-24	Amgen Inc	Sintesis de omecamtiv mecarbil.
US11225475B2 (en)	2017-08-07	2022-01-18	Alkermes, Inc.	Substituted pyridines as inhibitors of histone deacetylase
ES3053087T3 (en)	2018-03-05	2026-01-19	Wylder Nation Found	A fatty acid amide hydrolase (faahi) inhibitor for use in inhibiting the cellular accumulation of a sphingolipid in a subject that has lysosomal storage disease or disorder
EA039850B1 (ru) *	2018-04-30	2022-03-21	Эмджен Инк.	Синтез омекамтива мекарбила
US11858910B2 (en)	2018-08-24	2024-01-02	Sunshine Lake Pharma Co., Ltd.	Pyridinylmethylenepiperidine derivatives and uses thereof
EA202192047A1 (ru) *	2019-11-13	2021-12-08	Юманити Терапьютикс, Инк.	Соединения и их применение
EP4380571A1 (en) *	2021-08-04	2024-06-12	Jazz Pharmaceuticals Ireland Ltd.	Method of treating posttraumatic stress disorder
WO2024013567A1 (en) *	2022-07-15	2024-01-18	Jazz Pharmaceuticals Ireland Limited	Biaryl ether urea compounds as faah inhibitors
WO2024167423A1 (en)	2023-02-07	2024-08-15	Captor Therapeutics S.A.	Gspt1 degrader compounds
WO2025015420A1 (en)	2023-07-17	2025-01-23	Apogee Pharmaceuticals, Inc.	Novel fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB138405A (en)	1919-01-16	1920-02-12	Thomas Thompson	Improvements in or relating to suction or delivery valves for pumps
GB1138405A (en)	1966-12-28	1969-01-01	Ici Ltd	Morpholine derivatives
US3576810A (en) *	1968-06-20	1971-04-27	Robins Co Inc A H	1-substituted-3-(-4)-aroylpiperidines
GB1260886A (en)	1969-06-20	1972-01-19	Ici Ltd	Process for aryloxymethylmorpholine derivatives
BE759013R (fr)	1969-11-17	1971-05-17	Ici Ltd	Derives de la
BE758766A (fr)	1969-11-17	1971-05-10	Ici Ltd	Nouveaux derives de la morpholine et de la
US4116665A (en) *	1976-04-02	1978-09-26	Eli Lilly And Company	Method of regulating the growth of aquatic weeds with pyridine derivatives
IL56369A (en)	1978-01-20	1984-05-31	Erba Farmitalia	Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
GB8424979D0 (en) *	1984-10-03	1984-11-07	Wyeth John & Brother Ltd	Benzenesulphonamide derivatives
GB2167407B (en)	1984-11-22	1988-05-11	Erba Farmitalia	Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
NZ246434A (en)	1991-12-18	1996-02-27	Schering Corp	Imidazoylalkyl substituted by a six membered nitrogen containing heterocycle; pharmaceutical compositions and preparatory methods
DE4326344A1 (de)	1993-08-05	1995-02-09	Thomae Gmbh Dr K	Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU7823894A (en)	1993-08-27	1995-03-21	Vrije Universiteit	New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
SK282252B6 (sk)	1995-01-11	2001-12-03	Samjin Pharmaceutical Co., Ltd.	Piperazínové deriváty a farmaceutický prostriedok s ich obsahom
US6271015B1 (en) *	1995-06-12	2001-08-07	The Scripps Research Institute	Fatty-acid amide hydrolase
GB9526560D0 (en)	1995-12-27	1996-02-28	Bayer Ag	Use of 2-Amino-Heterocycles
FR2744449B1 (fr)	1996-02-02	1998-04-24	Pf Medicament	Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
US6207665B1 (en)	1997-06-12	2001-03-27	Schering Aktiengesellschaft	Piperazine derivatives and their use as anti-inflammatory agents
US6184242B1 (en) *	1997-09-04	2001-02-06	Syntex Usa (Llc)	2-(substituted-phenyl)amino-imidazoline derivatives
JP4778612B2 (ja)	1998-04-01	2011-09-21	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｐｄｅｉｖ阻害ピリジン誘導体
IL161840A0 (en)	1998-12-29	2005-11-20	Pharmacia & Upjohn Co Llc	Method for the preparation of aryl ethers
PE20001566A1 (es)	1999-03-26	2001-02-05	Ucb Sa	Piperazinas 1,4-sustituidas, piperidinas 1,4-sustituidas y 4-alquilidenilpiperidinas 1-sustituidas
MX339071B (es)	1999-03-31	2016-05-09	Janssen Pharmaceutica Nv	Almidon pregelatinizado en una formulacion de liberacion controlada.
US6632815B2 (en) *	1999-09-17	2003-10-14	Millennium Pharmaceuticals, Inc.	Inhibitors of factor Xa
AU7556800A (en)	1999-10-07	2001-05-10	Tadeka Chemical Industries, Ltd.	Amine derivatives
US6476041B1 (en)	1999-10-29	2002-11-05	Merck & Co., Inc.	1,4 substituted piperidinyl NMDA/NR2B antagonists
CA2397633A1 (en)	2000-01-18	2001-07-26	Pfizer Products Inc.	Corticotropin releasing factor antagonists
HUP0301391A3 (en)	2000-02-11	2010-03-29	Vertex Pharma	Piperazine and piperidine derivatives pharmaceutical compositions containing them and their use
GB0004297D0 (en) *	2000-02-23	2000-04-12	Ucb Sa	2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6552036B2 (en)	2000-03-03	2003-04-22	Ortho-Mcneil Pharmaceutical, Inc.	3-(Diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
JP2001303987A (ja) *	2000-04-21	2001-10-31	Toyota Motor Corp	筒内噴射式内燃機関のスロットル制御装置
AU2001264376A1 (en)	2000-06-15	2001-12-24	Chaconne Nsi Co., Ltd.	Urea derivative useful as an anti-cancer agent and process for preparing same
US20020183316A1 (en)	2000-10-27	2002-12-05	Kevin Pan	Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
EP1385520A4 (en)	2001-02-08	2007-03-21	Nps Pharma Inc	METHODS AND COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRICAL DISEASES AND FOR THE IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT THEREOF
JP2004534097A (ja) *	2001-07-09	2004-11-11	フアルマシア・イタリア・エツセ・ピー・アー	ＴＣＦ−４とβ−カテニンの相互作用阻害剤
AU2002363236A1 (en)	2001-10-30	2003-05-12	Millennium Pharmaceuticals, Inc.	Compounds, pharmaceutical compositions and methods of use therefor
US20040034101A1 (en) *	2001-11-05	2004-02-19	Cypress Bioscience, Inc.	Treatment and prevention of depression secondary to pain (DSP)
JP3865626B2 (ja) *	2001-11-08	2007-01-10	株式会社ベステックスキョーエイ	パイプ部材
FR2833261B1 (fr) *	2001-12-06	2004-07-02	Yang Ji Chemical Company Ltd	Nouveaux composes inhibiteurs specifiques de la phospholipase a2 secretee non pancreatique humaine du groupe ii
US20040063726A1 (en) *	2002-02-08	2004-04-01	Artman Linda D	Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
CA2476583C (en)	2002-03-13	2011-07-05	Kristof Van Emelen	Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
US6995144B2 (en)	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same
AU2003220184A1 (en)	2002-03-20	2003-10-08	Schering Aktiengesellschaft	Substituted piperazine antithrombotic pai-1 inhibitors
TWI283241B (en)	2002-05-29	2007-07-01	Tanabe Seiyaku Co	Novel piperidine compound
EP1572311A4 (en)	2002-10-21	2007-12-12	Janssen Pharmaceutica Nv	ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDHYDROLASE
TW200505902A (en) *	2003-03-20	2005-02-16	Schering Corp	Cannabinoid receptor ligands
PL377633A1 (pl)	2003-04-03	2006-02-06	Merck Patent Gmbh	Związki karbonylowe
SE0301442D0 (sv)	2003-05-16	2003-05-16	Astrazeneca Ab	Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
SE0301443D0 (sv)	2003-05-16	2003-05-16	Astrazeneca Ab	Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
GB0325287D0 (en)	2003-10-29	2003-12-03	Merck Sharp & Dohme	Therapeutic agents
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
GB2423083B (en) *	2003-12-03	2007-07-11	Cytopia Res Pty Ltd	Azole-based kinase inhibitors
WO2005075472A1 (en) *	2004-02-03	2005-08-18	Janssen Pharmaceutica, N.V.	3-(diheteroarylnethylene)-8-azabicyclo[3.2.1]octane and 3-(aryl)(heteroaryl)methylene)-8-azabicyclo[3.2.1]octane derivatives
CN1942470A (zh) *	2004-04-09	2007-04-04	默克公司	Akt活性抑制剂
WO2005115370A2 (en)	2004-04-23	2005-12-08	The Regents Of The University Of California	Compounds and methods for treating non-inflammatory pain using pparalpha agonists
SE0401343D0 (sv)	2004-05-25	2004-05-25	Astrazeneca Ab	Therapeutic compounds: Pyridine N oxide as scaffold
EA011671B1 (ru)	2004-06-04	2009-04-28	Арена Фармасьютикалз, Инк.	Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств
DE102004039789A1 (de)	2004-08-16	2006-03-02	Sanofi-Aventis Deutschland Gmbh	Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2316458A1 (en)	2004-09-20	2011-05-04	Xenon Pharmaceuticals Inc.	Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
DE102004045796A1 (de)	2004-09-22	2006-03-23	Merck Patent Gmbh	Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
WO2006035303A1 (en)	2004-09-29	2006-04-06	Ranbaxy Laboratories Limited	Muscarinic receptor antagonists
US7491720B2 (en) *	2004-10-29	2009-02-17	Banyu Pharmaceutical Co., Ltd.	Aminopyridine derivatives having Aurora A selective inhibitory action
EP1657241A1 (en)	2004-11-03	2006-05-17	Schering Aktiengesellschaft	Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
EP1655297A1 (en)	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
TW200633990A (en)	2004-11-18	2006-10-01	Takeda Pharmaceuticals Co	Amide compound
US20060167044A1 (en) *	2004-12-20	2006-07-27	Arnaiz Damian O	Piperidine derivatives and their use as anti-inflammatory agents
KR20070091038A (ko)	2004-12-24	2007-09-06	프로시디온 리미티드	Ｇ-단백질 결합 수용체(ｇｐｒ116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도
CA2589748C (en)	2004-12-24	2013-08-13	Astrazeneca Ab	Heterocyclic compounds as ccr2b antagonists
WO2006074025A1 (en) *	2004-12-30	2006-07-13	Janssen Pharmaceutica N.V.	Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
CA2597131A1 (en)	2005-02-10	2006-08-17	Warner-Lambert Company Llc	Fatty acid amide hydrolase assay
EP1866314B1 (en) *	2005-02-16	2010-09-15	NeuroSearch A/S	Novel diazabicyclic aryl derivatives and their medical use
MX2007010076A (es)	2005-02-17	2007-10-16	Astellas Pharma Inc	Derivado de heterociclico-1-carboxilato que contiene nitrogeno no aromatico de piridilo.
US20090082435A1 (en)	2005-04-28	2009-03-26	The Regents Of The University Of California	Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
GB0510139D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
WO2006129842A1 (ja)	2005-06-01	2006-12-07	Banyu Pharmaceutical Co., Ltd.	オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
JPWO2006137465A1 (ja)	2005-06-24	2009-01-22	塩野義製薬株式会社	含窒素複素環誘導体
US7541359B2 (en) *	2005-06-30	2009-06-02	Janssen Pharmaceutica N.V.	N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase
AU2006264649A1 (en)	2005-06-30	2007-01-11	Prosidion Limited	GPCR agonists
CN101296914B (zh)	2005-08-26	2012-07-18	盐野义制药株式会社	具有ppar激动活性的衍生物
US7131609B1 (en)	2005-08-31	2006-11-07	Kimberly-Clark Worldwide, Inc.	Dispenser for sheet material
US20070155707A1 (en)	2005-12-29	2007-07-05	Kadmus Pharmaceuticals, Inc.	Ionizable inhibitors of fatty acid amide hydrolase
MX2008008529A (es)	2005-12-29	2008-09-26	Organon Nv	Inhibidores de amida hidrolasa de acido graso.
WO2007103456A2 (en)	2006-03-06	2007-09-13	Trimeris, Inc.	Piperazine and piperidine biaryl derivatives
TW200811157A (en) *	2006-05-05	2008-03-01	Astrazeneca Ab	mGluR5 modulators I
US20080076924A1 (en)	2006-06-30	2008-03-27	Patrick Betschmann	Piperazines as P2X7 antagonists
WO2008021625A2 (en)	2006-08-18	2008-02-21	N.V. Organon	Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
WO2008024139A2 (en)	2006-08-18	2008-02-28	N.V. Organon	Inhibitors of fatty acid amide hydrolase
US7888394B2 (en)	2006-08-21	2011-02-15	N.V. Organon	Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
JPWO2008023720A1 (ja)	2006-08-23	2010-01-14	アステラス製薬株式会社	ウレア化合物又はその塩
US20080089845A1 (en)	2006-09-07	2008-04-17	N.V. Organon	Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
US20090099240A1 (en)	2006-10-02	2009-04-16	N.V. Organon	Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity
JO3598B1 (ar)	2006-10-10	2020-07-05	Infinity Discovery Inc	الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
GEP20125425B (en)	2006-10-18	2012-03-26	Pfizer Prod Inc	Biaryl ether urea compounds
EP2096915A1 (en)	2006-11-20	2009-09-09	N.V. Organon	Metabolically-stabilized inhibitors of fatty acid amide hydrolase
NZ552238A (en)	2006-12-20	2009-07-31	Seperex Nutritionals Ltd	An extract
JP2010528114A (ja)	2007-05-25	2010-08-19	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	脂肪酸アミド加水分解酵素のヘテロアリール置換尿素モジュレータ

2007
- 2007-10-05 GE GEAP200711226A patent/GEP20125425B/en unknown
- 2007-10-05 ES ES07848827T patent/ES2357340T3/es active Active
- 2007-10-05 NZ NZ575624A patent/NZ575624A/en unknown
- 2007-10-05 DK DK07848827.7T patent/DK2076508T3/da active
- 2007-10-05 MX MX2009004233A patent/MX2009004233A/es active IP Right Grant
- 2007-10-05 EP EP07848827A patent/EP2076508B1/en active Active
- 2007-10-05 AP AP2009004821A patent/AP2780A/xx active
- 2007-10-05 KR KR1020097007835A patent/KR101181194B1/ko active Active
- 2007-10-05 ME MEP-2011-49A patent/ME01308B/me unknown
- 2007-10-05 AT AT07848827T patent/ATE493984T1/de active
- 2007-10-05 CN CN2007800389592A patent/CN101595102B/zh active Active
- 2007-10-05 DE DE602007011793T patent/DE602007011793D1/de active Active
- 2007-10-05 WO PCT/IB2007/003202 patent/WO2008047229A2/en not_active Ceased
- 2007-10-05 RS RSP-2009/0154A patent/RS20090154A/sr unknown
- 2007-10-05 HR HR20110158T patent/HRP20110158T1/hr unknown
- 2007-10-05 RS RS20110107A patent/RS51647B/sr unknown
- 2007-10-05 CA CA2663984A patent/CA2663984C/en active Active
- 2007-10-05 AU AU2007311591A patent/AU2007311591B2/en active Active
- 2007-10-05 JP JP2009532909A patent/JP4434313B2/ja active Active
- 2007-10-05 SI SI200730534T patent/SI2076508T1/sl unknown
- 2007-10-05 PT PT07848827T patent/PT2076508E/pt unknown
- 2007-10-05 EA EA200970296A patent/EA015488B1/ru not_active IP Right Cessation
- 2007-10-05 BR BRPI0717596A patent/BRPI0717596B8/pt active IP Right Grant
- 2007-10-05 PL PL07848827T patent/PL2076508T3/pl unknown
- 2007-10-17 TW TW096138933A patent/TWI404715B/zh active
- 2007-10-17 UY UY30649A patent/UY30649A1/es not_active Application Discontinuation
- 2007-10-17 PE PE2007001407A patent/PE20081265A1/es active IP Right Grant
- 2007-10-17 AR ARP070104596A patent/AR063331A1/es active IP Right Grant
- 2007-10-18 US US11/874,577 patent/US8044052B2/en active Active
- 2007-10-18 CL CL200703000A patent/CL2007003000A1/es unknown
- 2007-10-19 HN HN2007000407A patent/HN2007000407A/es unknown
2009
- 2009-03-18 IL IL197664A patent/IL197664A/en active IP Right Grant
- 2009-03-27 MY MYPI20091261A patent/MY145460A/en unknown
- 2009-03-31 CR CR10701A patent/CR10701A/es unknown
- 2009-04-14 ZA ZA200902548A patent/ZA200902548B/xx unknown
- 2009-04-14 TN TNP2009000138A patent/TN2009000138A1/fr unknown
- 2009-04-17 MA MA31798A patent/MA30801B1/fr unknown
- 2009-04-20 NO NO20091560A patent/NO342266B1/no unknown
2011
- 2011-02-08 CY CY20111100140T patent/CY1111170T1/el unknown
2014
- 2014-06-27 CR CR20140313A patent/CR20140313A/es unknown

Also Published As

Publication number	Publication date
DE602007011793D1 (de)	2011-02-17
US20080261941A1 (en)	2008-10-23
JP4434313B2 (ja)	2010-03-17
BRPI0717596A2 (pt)	2013-10-29
CN101595102A (zh)	2009-12-02
ME01308B (me)	2013-12-20
HRP20110158T1 (hr)	2011-04-30
EP2076508B1 (en)	2011-01-05
BRPI0717596B8 (pt)	2021-05-25
KR101181194B1 (ko)	2012-09-18
PL2076508T3 (pl)	2011-05-31
CL2007003000A1 (es)	2008-06-13
AU2007311591B2 (en)	2010-10-07
PT2076508E (pt)	2011-03-07
UY30649A1 (es)	2008-05-31
AR063331A1 (es)	2009-01-21
CA2663984A1 (en)	2008-04-24
HK1139652A1 (en)	2010-09-24
EA200970296A1 (ru)	2009-10-30
WO2008047229A2 (en)	2008-04-24
TWI404715B (zh)	2013-08-11
SI2076508T1 (sl)	2011-04-29
NO342266B1 (no)	2018-04-30
BRPI0717596B1 (pt)	2020-04-14
WO2008047229A3 (en)	2008-09-04
CN101595102B (zh)	2013-08-07
EA015488B1 (ru)	2011-08-30
AU2007311591A1 (en)	2008-04-24
IL197664A0 (en)	2009-12-24
AP2009004821A0 (en)	2009-04-30
TN2009000138A1 (fr)	2010-10-18
EP2076508A2 (en)	2009-07-08
AP2780A (en)	2013-09-30
NZ575624A (en)	2012-02-24
HN2007000407A (es)	2010-10-04
MY145460A (en)	2012-02-15
DK2076508T3 (da)	2011-02-21
RS20090154A (sr)	2010-10-31
MX2009004233A (es)	2009-08-12
TW200825062A (en)	2008-06-16
ES2357340T3 (es)	2011-04-25
JP2010506896A (ja)	2010-03-04
KR20090061051A (ko)	2009-06-15
CR20140313A (es)	2014-07-28
PE20081265A1 (es)	2008-09-17
ZA200902548B (en)	2010-03-31
US8044052B2 (en)	2011-10-25
GEP20125425B (en)	2012-03-26
NO20091560L (no)	2009-05-15
ATE493984T1 (de)	2011-01-15
IL197664A (en)	2013-01-31
RS51647B (sr)	2011-10-31
CY1111170T1 (el)	2015-06-11
CA2663984C (en)	2012-02-21
MA30801B1 (fr)	2009-10-01

Publication	Publication Date	Title
LTC2004635I2 (lt)	2021-05-25	Pakeistieji enaminokarbonilo junginiai
CR10841A (es)	2009-06-30	Imidazotriazinas imidazopirimidinas inhibidores de cinasa
BRPI0815042A2 (pt)	2015-02-10	Compostos de pirazol
ATE524477T1 (de)	2011-09-15	Aziridinylepothilonverbindungen
EP2091425A4 (en)	2012-07-25	Measurement apparatus
DK4282332T3 (da)	2024-06-24	Analytsensor
CR10831A (es)	2009-06-18	INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
EP1982167A4 (en)	2010-06-30	BIOSENSOR
DK2064228T3 (da)	2012-12-10	Syntetiske peptidamider
DK2016080T3 (da)	2010-11-22	Dihydropyrazolopyrimidinon-derivater
ATE483711T1 (de)	2010-10-15	Spiroindolinonderivate
BRPI0714512A2 (pt)	2015-06-16	Compostos químicos
ATE469905T1 (de)	2010-06-15	Pyridopyrimidinonderivate
DE602006021235D1 (de)	2011-05-19	Kristallglasgegenstand
ATE512135T1 (de)	2011-06-15	Spiroindolinonderivate
DK2035394T3 (da)	2009-10-05	2-pyrazincarboxamidderivater
DE502007004319D1 (de)	2010-08-19	Fühler
ATE544764T1 (de)	2012-02-15	5-hydroxymethyloxazolidin-2-onderivate
EP2017608A4 (en)	2012-12-12	Biosensor
DE602007010950D1 (de)	2011-01-13	Dosierpumpe
BRPI0814718A2 (pt)	2015-02-24	Derivados de isoxazol-imidazol
EP2013572A4 (en)	2012-08-08	CALIBRATION
PT2792662T (pt)	2016-07-07	Compostos de morfinano
EP2017607A4 (en)	2009-08-05	BIOSENSOR
PT2062053E (pt)	2013-02-11	Métodos de imunoensaio melhorados